Listed

Pelthos Therapeutics Inc.

PTHSNYSECIK 1919246HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$15.6m, Q2 FY2026
Operating income−$17.3m, Q2 FY2026
Net income−$23.4m, Q2 FY2026
Pelthos Therapeutics Inc., income statement, quarterly
Line itemUnitperiod not labelled2023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$mnot reportednot reportednot reportednot reportednot reportednot reported0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure0.3Revenue, Q3 FY2025, three months to 2025-09-30$294.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure16.5Revenue, Q4 FY2025, three months to 2025-12-31$16.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure10.9Revenue, Q1 FY2026, three months to 2026-03-31$10.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure15.6Revenue, Q2 FY2026, three months to 2026-06-30$15.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Cost of revenue$mnot reportednot reportednot reportednot reportednot reportednot reported0.0Cost of revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure0.0Cost of revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure2.3Cost of revenue, Q3 FY2025, three months to 2025-09-30$2.3m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure1.7Cost of revenue, Q4 FY2025, three months to 2025-12-31$1.7m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure1.7Cost of revenue, Q1 FY2026, three months to 2026-03-31$1.7m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure3.6Cost of revenue, Q2 FY2026, three months to 2026-06-30$3.6m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Research and development$m0.0Research and development, period not labelled, three months to 2023-09-30$49.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0001753926-24-001883.Report this figure2.3Research and development, Q4 FY2023, three months to 2023-12-31$2.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-27, accession 0001753926-25-000503. Derived: 12-month figure less the 9-month figure.Report this figure0.5Research and development, Q1 FY2024, three months to 2024-03-31$466.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001753926-25-000790.Report this figure0.0Research and development, Q2 FY2024, three months to 2024-06-30$13.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-13, accession 0001753926-25-001326.Report this figure0.4Research and development, Q3 FY2024, three months to 2024-09-30$415.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure0.3Research and development, Q4 FY2024, three months to 2024-12-31$285.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure0.2Research and development, Q1 FY2025, three months to 2025-03-31$194.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure0.5Research and development, Q2 FY2025, three months to 2025-06-30$515.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure0.1Research and development, Q3 FY2025, three months to 2025-09-30$145.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure0.4Research and development, Q4 FY2025, three months to 2025-12-31$374.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure0.2Research and development, Q1 FY2026, three months to 2026-03-31$186.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure0.6Research and development, Q2 FY2026, three months to 2026-06-30$600.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Selling, general and administrative$mnot reportednot reportednot reportednot reported1.6Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$1.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure1.5Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$1.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure1.6Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$1.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure2.7Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$2.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure19.6Selling, general and administrative, Q3 FY2025, three months to 2025-09-30$19.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure18.5Selling, general and administrative, Q4 FY2025, three months to 2025-12-31$18.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure21.1Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$21.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure27.7Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$27.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Operating income$m(1.3)Operating income, period not labelled, three months to 2023-09-30−$1.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001753926-24-001883.Report this figure(3.9)Operating income, Q4 FY2023, three months to 2023-12-31−$3.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-27, accession 0001753926-25-000503. Derived: 12-month figure less the 9-month figure.Report this figure(1.9)Operating income, Q1 FY2024, three months to 2024-03-31−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001753926-25-000790.Report this figure(1.8)Operating income, Q2 FY2024, three months to 2024-06-30−$1.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-13, accession 0001753926-25-001326.Report this figure(2.0)Operating income, Q3 FY2024, three months to 2024-09-30−$2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure(1.8)Operating income, Q4 FY2024, three months to 2024-12-31−$1.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure(1.8)Operating income, Q1 FY2025, three months to 2025-03-31−$1.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(3.2)Operating income, Q2 FY2025, three months to 2025-06-30−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure(15.4)Operating income, Q3 FY2025, three months to 2025-09-30−$15.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure(12.0)Operating income, Q4 FY2025, three months to 2025-12-31−$12.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure(13.1)Operating income, Q1 FY2026, three months to 2026-03-31−$13.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(17.3)Operating income, Q2 FY2026, three months to 2026-06-30−$17.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Interest expense$mnot reportednot reported0.0Interest expense, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-05-13, accession 0001753926-25-000790.Report this figurenot reported0.0Interest expense, Q3 FY2024, three months to 2024-09-30$39.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure0.1Interest expense, Q4 FY2024, three months to 2024-12-31$108.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2025, three months to 2025-03-31$1.8k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-05-13, accession 0001753926-25-000790.Report this figure0.2Interest expense, Q2 FY2025, three months to 2025-06-30$218.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure1.3Interest expense, Q3 FY2025, three months to 2025-09-30$1.3m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure1.3Interest expense, Q4 FY2025, three months to 2025-12-31$1.3m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure2.4Interest expense, Q1 FY2026, three months to 2026-03-31$2.4m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure2.4Interest expense, Q2 FY2026, three months to 2026-06-30$2.4m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reported0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure(0.5)Income tax, Q3 FY2025, three months to 2025-09-30−$465.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure(6.9)Income tax, Q4 FY2025, three months to 2025-12-31−$6.9m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Net income$m(1.4)Net income, period not labelled, three months to 2023-09-30−$1.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001753926-24-001883.Report this figure(4.0)Net income, Q4 FY2023, three months to 2023-12-31−$4.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-27, accession 0001753926-25-000503. Derived: 12-month figure less the 9-month figure.Report this figure(2.6)Net income, Q1 FY2024, three months to 2024-03-31−$2.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure(1.8)Net income, Q2 FY2024, three months to 2024-06-30−$1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure(1.7)Net income, Q3 FY2024, three months to 2024-09-30−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure(1.9)Net income, Q4 FY2024, three months to 2024-12-31−$1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure(2.0)Net income, Q1 FY2025, three months to 2025-03-31−$2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure(3.4)Net income, Q2 FY2025, three months to 2025-06-30−$3.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure(16.2)Net income, Q3 FY2025, three months to 2025-09-30−$16.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure(21.7)Net income, Q4 FY2025, three months to 2025-12-31−$21.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure(25.1)Net income, Q1 FY2026, three months to 2026-03-31−$25.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure(23.4)Net income, Q2 FY2026, three months to 2026-06-30−$23.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Diluted EPS$ per sharenot reportednot reported(0.55)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001753926-25-000790.Report this figure(3.07)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$3.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-13, accession 0001753926-25-001326.Report this figure(2.93)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$2.93 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figurenot reported(3.21)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$3.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(5.29)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$5.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure(5.30)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$5.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figurenot reported(7.57)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$7.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(6.62)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$6.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Basic EPS$ per share(1.44)Basic EPS, period not labelled, three months to 2023-09-30−$1.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001753926-24-001883.Report this figurenot reported(0.55)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.55 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0001753926-25-000790.Report this figure(3.07)Basic EPS, Q2 FY2024, three months to 2024-06-30−$3.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-13, accession 0001753926-25-001326.Report this figure(2.93)Basic EPS, Q3 FY2024, three months to 2024-09-30−$2.93 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figurenot reported(3.21)Basic EPS, Q1 FY2025, three months to 2025-03-31−$3.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(5.29)Basic EPS, Q2 FY2025, three months to 2025-06-30−$5.29 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure(5.30)Basic EPS, Q3 FY2025, three months to 2025-09-30−$5.30 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figurenot reported(7.57)Basic EPS, Q1 FY2026, three months to 2026-03-31−$7.57 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(6.62)Basic EPS, Q2 FY2026, three months to 2026-06-30−$6.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure

Balance sheet

Cash and equivalents$24.2m, Q2 FY2026
Shareholders' equity−$1.5m, Q2 FY2026
Pelthos Therapeutics Inc., balance sheet, quarterly
Line itemUnitperiod not labelled2023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$mnot reported0.1Cash and equivalents, FY2023, at 2023-12-31$100.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0001753926-24-001883.Report this figure3.8Cash and equivalents, Q1 FY2024, at 2024-03-31$3.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-15, accession 0001753926-24-000976.Report this figure2.4Cash and equivalents, Q2 FY2024, at 2024-06-30$2.4m. XBRL concept us-gaap:Cash. 10-Q filed 2024-08-13, accession 0001753926-24-001423.Report this figure1.3Cash and equivalents, Q3 FY2024, at 2024-09-30$1.3m. XBRL concept us-gaap:Cash. 10-Q filed 2024-11-13, accession 0001753926-24-001883.Report this figure0.5Cash and equivalents, FY2024, at 2024-12-31$513.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure0.1Cash and equivalents, Q1 FY2025, at 2025-03-31$131.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure0.1Cash and equivalents, Q2 FY2025, at 2025-06-30$59.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure14.2Cash and equivalents, Q3 FY2025, at 2025-09-30$14.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure18.0Cash and equivalents, FY2025, at 2025-12-31$18.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure32.0Cash and equivalents, Q1 FY2026, at 2026-03-31$32.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure24.2Cash and equivalents, Q2 FY2026, at 2026-06-30$24.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Current assets$mnot reported0.1Current assets, FY2023, at 2023-12-31$96.4k. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-27, accession 0001753926-25-000503.Report this figure4.0Current assets, Q1 FY2024, at 2024-03-31$4.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-15, accession 0001753926-24-000976.Report this figure2.6Current assets, Q2 FY2024, at 2024-06-30$2.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0001753926-24-001423.Report this figure2.1Current assets, Q3 FY2024, at 2024-09-30$2.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001753926-24-001883.Report this figure1.4Current assets, FY2024, at 2024-12-31$1.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure0.9Current assets, Q1 FY2025, at 2025-03-31$911.2k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0001753926-25-000790.Report this figure0.8Current assets, Q2 FY2025, at 2025-06-30$822.9k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-13, accession 0001753926-25-001326.Report this figure49.8Current assets, Q3 FY2025, at 2025-09-30$49.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure53.4Current assets, FY2025, at 2025-12-31$53.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure69.8Current assets, Q1 FY2026, at 2026-03-31$69.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure63.4Current assets, Q2 FY2026, at 2026-06-30$63.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Total assets$mnot reported0.1Total assets, FY2023, at 2023-12-31$96.4k. XBRL concept us-gaap:Assets. 10-K filed 2025-03-27, accession 0001753926-25-000503.Report this figure4.0Total assets, Q1 FY2024, at 2024-03-31$4.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-15, accession 0001753926-24-000976.Report this figure2.6Total assets, Q2 FY2024, at 2024-06-30$2.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0001753926-24-001423.Report this figure2.1Total assets, Q3 FY2024, at 2024-09-30$2.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001753926-24-001883.Report this figure1.4Total assets, FY2024, at 2024-12-31$1.4m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure0.9Total assets, Q1 FY2025, at 2025-03-31$911.2k. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0001753926-25-000790.Report this figure0.8Total assets, Q2 FY2025, at 2025-06-30$822.9k. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-13, accession 0001753926-25-001326.Report this figure126Total assets, Q3 FY2025, at 2025-09-30$126.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure130Total assets, FY2025, at 2025-12-31$130.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure145Total assets, Q1 FY2026, at 2026-03-31$145.4m. XBRL concept us-gaap:Assets. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure137Total assets, Q2 FY2026, at 2026-06-30$137.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Current liabilities$mnot reported6.5Current liabilities, FY2023, at 2023-12-31$6.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-27, accession 0001753926-25-000503.Report this figure2.9Current liabilities, Q1 FY2024, at 2024-03-31$2.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-15, accession 0001753926-24-000976.Report this figure2.8Current liabilities, Q2 FY2024, at 2024-06-30$2.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0001753926-24-001423.Report this figure3.6Current liabilities, Q3 FY2024, at 2024-09-30$3.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001753926-24-001883.Report this figure4.1Current liabilities, FY2024, at 2024-12-31$4.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure5.1Current liabilities, Q1 FY2025, at 2025-03-31$5.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0001753926-25-000790.Report this figure7.3Current liabilities, Q2 FY2025, at 2025-06-30$7.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-13, accession 0001753926-25-001326.Report this figure24.8Current liabilities, Q3 FY2025, at 2025-09-30$24.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure26.0Current liabilities, FY2025, at 2025-12-31$26.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure25.0Current liabilities, Q1 FY2026, at 2026-03-31$25.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure32.0Current liabilities, Q2 FY2026, at 2026-06-30$32.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Total liabilities$mnot reported6.5Total liabilities, FY2023, at 2023-12-31$6.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-27, accession 0001753926-25-000503.Report this figure2.9Total liabilities, Q1 FY2024, at 2024-03-31$2.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-15, accession 0001753926-24-000976.Report this figure2.8Total liabilities, Q2 FY2024, at 2024-06-30$2.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0001753926-24-001423.Report this figure3.6Total liabilities, Q3 FY2024, at 2024-09-30$3.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001753926-24-001883.Report this figure4.1Total liabilities, FY2024, at 2024-12-31$4.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure5.1Total liabilities, Q1 FY2025, at 2025-03-31$5.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0001753926-25-000790.Report this figure7.3Total liabilities, Q2 FY2025, at 2025-06-30$7.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-13, accession 0001753926-25-001326.Report this figure68.2Total liabilities, Q3 FY2025, at 2025-09-30$68.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure91.5Total liabilities, FY2025, at 2025-12-31$91.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure126Total liabilities, Q1 FY2026, at 2026-03-31$126.1m. XBRL concept us-gaap:Liabilities. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure139Total liabilities, Q2 FY2026, at 2026-06-30$138.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Shareholders' equity$m(5.9)Shareholders' equity, period not labelled, at 2023-09-30−$5.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001753926-24-001883.Report this figure(6.4)Shareholders' equity, FY2023, at 2023-12-31−$6.4m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure1.1Shareholders' equity, Q1 FY2024, at 2024-03-31$1.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure(0.2)Shareholders' equity, Q2 FY2024, at 2024-06-30−$184.0k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure(1.4)Shareholders' equity, Q3 FY2024, at 2024-09-30−$1.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure(2.7)Shareholders' equity, FY2024, at 2024-12-31−$2.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure(4.2)Shareholders' equity, Q1 FY2025, at 2025-03-31−$4.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure(6.5)Shareholders' equity, Q2 FY2025, at 2025-06-30−$6.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure58.3Shareholders' equity, Q3 FY2025, at 2025-09-30$58.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure38.9Shareholders' equity, FY2025, at 2025-12-31$38.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure19.3Shareholders' equity, Q1 FY2026, at 2026-03-31$19.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure(1.5)Shareholders' equity, Q2 FY2026, at 2026-06-30−$1.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure

Cash flow

Operating cash flow−$7.7m, Q2 FY2026
Capital expenditure$2.0k, Q2 FY2026
Pelthos Therapeutics Inc., cash flow, quarterly
Line itemUnitperiod not labelled2023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(0.3)Operating cash flow, period not labelled, three months to 2023-09-30−$257.2k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001753926-24-001883. Derived: 9-month figure less the 6-month figure.Report this figure(0.4)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$356.8k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-27, accession 0001753926-25-000503. Derived: 12-month figure less the 9-month figure.Report this figure(2.0)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001753926-25-000790.Report this figure(3.0)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$3.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-13, accession 0001753926-25-001326. Derived: 6-month figure less the 3-month figure.Report this figure(0.2)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$177.7k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001753926-25-001764. Derived: 9-month figure less the 6-month figure.Report this figure(0.7)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$670.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure(0.6)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$632.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(0.4)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$447.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001919246-26-000113. Derived: 6-month figure less the 3-month figure.Report this figure(15.3)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$15.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001753926-25-001764. Derived: 9-month figure less the 6-month figure.Report this figure(6.3)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$6.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure(13.1)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(7.7)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$7.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001919246-26-000113. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$mnot reportednot reportednot reportednot reportednot reportednot reported0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001919246-26-000113. Derived: 6-month figure less the 3-month figure.Report this figurenot reportednot reported0.2Capital expenditure, Q1 FY2026, three months to 2026-03-31$194.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001919246-26-000113. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)3.54m, Q2 FY2026
Pelthos Therapeutics Inc., shares, quarterly
Line itemUnitQ1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)k shares4,691Diluted shares (weighted), Q1 FY2024, three months to 2024-03-314,690,989 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0001753926-25-000790.Report this figure577Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30577,371 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-13, accession 0001753926-25-001326.Report this figure579Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30579,229 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure613Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31612,889 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure652Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30651,921 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure3,061Diluted shares (weighted), Q3 FY2025, three months to 2025-09-303,061,488 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure3,312Diluted shares (weighted), Q1 FY2026, three months to 2026-03-313,311,742 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure3,539Diluted shares (weighted), Q2 FY2026, three months to 2026-06-303,539,464 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure

Shares outstanding: 3.83mShares outstanding, period not labelled, at 2026-08-103,828,469 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure at Aug 10, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.